Dr Marcus Delatte

SpecialityVP, Regulatory Strategy at Allucent

Dr. Delatte became a scientist based on his interests in understanding the effects of drugs in organisms and in impacting public health.  His interests led him to earn a PhD at the Louisiana State University Health Sciences Center (2004) in Pharmacology and to complete a post-doctoral fellowship at the Harvard Medical School/McLean Hospital (2008).  As a graduate student, he designed and conducted experiments focused on understanding the effects of cannabinoids on simple and complex behaviors in various animal species.  Findings from these studies provided him with an in-depth understanding of the effects of different cannabinoids on behavior studied under various contexts.  As a postdoctoral fellow in the Department of Psychiatry at the McLean Hospital/Harvard Medical School, he collaborated with medicinal chemists that developed and provided novel cannabinoids, which he evaluated using behavioral and physiological endpoints in monkeys.  This research focused on the evaluation of cannabinergic drugs synthesized via a collaborative project with a Chemistry laboratory that developed potential pharmacotherapies for cannabis addiction.  These experiences increased his drive to help develop treatment approaches for patients with substance-abuse disorders and other indications.  Following the completion of his fellowship, Dr. Delatte joined the Food and Drug Administration (FDA) as a Pharmacology/Toxicology Reviewer.  At the FDA, he reviewed applications to conduct clinical studies, as well as to acquire marketing approval for pharmaceutical products.  These applications typically covered therapeutics developed as antidote, analgesic, anesthetic, wound healing, neurolytic, sclerotic, or addiction medications.  These experiences and others positioned Dr. Delatte to enter the private sector and to rise to Vice President of Regulatory Strategy at Allucent (e.g., Contract Research Organization).  He continues to advise domestic and international clientele on drug product development and strategy for products intended to treat the mentioned indications and others (e.g., oncology, infectious diseases), as well as on many other regulatory- and safety-related issues.  Dr. Delatte continues to work hard to expand his impact on public health issues by teaching, advising individual scientists and companies, and by mentoring young and established scientists.

All session
by Dr Marcus Delatte